EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against Respiratory Syncytial Virus, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years

Jaya Goswami, Jose F Cardona iD, Jorge Caso, Denise C Hsu, Alana K Simorellis, Lauren Wilson, Rakesh Dhar, Xiaowei Wang, Archana Kapoor, Avi Collins, Vinicius Righi, Lan Lan und 7 weitere

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciaf515 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Jaya Goswami und 18 weiteren Autor:innen. Beteiligte Einrichtung: Moderna, Inc., Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Immunization, Secondary, Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus, Human. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Moderna Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background mRNA-1345 is a respiratory syncytial virus (RSV) vaccine approved for prevention of RSV-associated lower respiratory tract disease in individuals ≥ 60 years. Durability of efficacy is being evaluated in clinical trials. Data on revaccination in adults are needed.

Methods

This open-label, phase 3 trial evaluated revaccination with 50 µg mRNA-1345 administered 12 months after primary vaccination in participants aged ≥50 years. The primary objectives were the immunogenicity (RSV-A and RSV-B neutralizing antibody [nAb] responses), tolerability, and safety of revaccination.

Results

Overall, 543 participants were revaccinated. Most adverse reactions were mild/moderate (median duration, 2 days), with no new safety concerns identified. Coprimary immunogenicity endpoints met prespecified noninferiority criteria based on Day 29 geometric mean titer ratios (GMRs; revaccination vs primary vaccination). At Day 29, nAb GMRs (95% confidence interval [CI]) were 1.08 (1.0–1.17) for RSV-A and 0.91 (.84–.98) for RSV-B. Seroresponse rates (≥4-fold rise from baseline; 95% CI) at Day 29 were 77.5% (73.7–81.0) for RSV-A and 47.5% (43.2–51.9) for RSV-B, with a ≥2-fold rise in titers observed in 91.6% (88.9–93.8) and 69.8% (65.7–73.8) of participants, respectively. Following primary vaccination, RSV nAb titers increased by Day 29 and gradually declined over 12 months, yet remained above baseline levels. Revaccination at 12 months increased nAb titers, similar to the response observed after the primary dose.

Conclusions

Revaccination of adults ≥ 50 years with mRNA-1345 was well tolerated, with a safety profile consistent with the primary dose. Respiratory syncytial virus nAb at Day 29 was noninferior to those after a primary mRNA-1345 dose, with antibody response persisting for 12 months. Clinical Trials Registration ClinicalTrials.gov: NCT05330975.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunization, SecondaryRespiratory Syncytial Virus VaccinesRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus, HumanImmunogenicity, VaccineHumansMiddle AgedMaleFemaleAgedAntibodies, ViralAntibodies, NeutralizingVaccines, SyntheticAged, 80 and overmRNA Vaccines

Stichwörter der Autor:innen

immunogenicitymRNA RSV vaccinerespiratory syncytial virusrevaccinationsafety

Substanzen

Respiratory Syncytial Virus VaccinesAntibodies, ViralAntibodies, NeutralizingVaccines, SyntheticmRNA-1345 respiratory syncytial virus vaccinemRNA Vaccines

Autor:innen und Institutionen

  • Moderna, Inc., Cambridge, Massachusetts, USA.
  • Indago Research and Health Center, Hialeah, Florida, USA.
  • Suncoast Research Associates LLC, Miami, Florida, USA.

ORCID-Profile: Jose F Cardona, Eleanor Wilson

Förderung

  • Moderna Inc

Zitieren

APA

Goswami, J., Cardona, J. F., Caso, J., Hsu, D. C., Simorellis, A. K., Wilson, L., Dhar, R., Wang, X., Kapoor, A., Collins, A., Righi, V., Lan, L., Du, J., Zhou, H., Stoszek, S. K., Shaw, C. A., Reuter, C., Wilson, E., & Das, R. (2026). Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against Respiratory Syncytial Virus, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf515

Vancouver

Goswami J, Cardona JF, Caso J, Hsu DC, Simorellis AK, Wilson L, et al. Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against Respiratory Syncytial Virus, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciaf515

BibTeX
@article{Goswami2026,
  author = {Goswami, Jaya and Cardona, Jose F and Caso, Jorge and Hsu, Denise C and Simorellis, Alana K and Wilson, Lauren and Dhar, Rakesh and Wang, Xiaowei and Kapoor, Archana and Collins, Avi and Righi, Vinicius and Lan, Lan and Du, Jiejun and Zhou, Honghong and Stoszek, Sonia K and Shaw, Christine A and Reuter, Caroline and Wilson, Eleanor and Das, Rituparna},
  title = {Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against Respiratory Syncytial Virus, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciaf515}
}
Kostenlos starten →